







CHEMMEDCHEM

CHEMISTRY ENABLING DRUG DISCOVERY



EFMC | ISMC 2012
XXIIInd
International Symposium
on Medicinal Chemistry

Berlin, Germany September 2-6, 2012



ISMC 2012 Book of Abstracts

A Journal of



ChemPubSoc
Europe

 WILEY-VCH

FCT and FEDER (European Fund for Regional Development)-COMPETE/QREN/EU are acknowledged for financial support through the research unities PEst-C/QUI/UI686/2011 and PEst-OE/AGR/UI0690/2011, the research project PTDC/QUI- QUI/111060/2009 and the postdoctoral grant to R.C.C. (SFRH/BPD/68344/2010).

References

- [1] G. Giamas, Y. L. Man, H. Hirner, J. Bischof, K. Kramer, K. Khan, S. S. L. Ahmed, et al., *Cell. Signalling* **2010**, *22*, 984–1002.


P023

Synthesis of Novel 1-Aryl-3-[2-, 3- or 4-(thieno[3,2-*b*]pyridin-7-ylthio)phenyl]ureas and Evaluation as VEGFR2 Tyrosine Kinase Inhibitors

Daniela Peixoto,^[a] Maria-João R.P. Queiroz,^[a]
Rui M.V. Abreu,^[b] Hugo J.C. Froufe,^[b]
Ricardo C. Calhelha,^[a,b] Isabel C.F.R. Ferreira^[b]

[a] Centro de Química, Universidade do Minho, Campus de Gualtar 4710-057 Braga, Portugal

[b] CIMO/ESA, Inst. Politécnico de Bragança Campus de Santa Apolónia, Apt 1172, 5301-855 Bragança, Portugal



Vascular endothelial growth factor receptor 2 (VEGFR2) tyrosine kinase is involved in cancer and in angiogenesis.^[1] Herein, we report the synthesis of novel 1-aryl-3-[2-, 3- or 4-(thieno[3,2-*b*]pyridin-7-ylthio)phenyl]ureas as VEGFR2 inhibitors by promoting the regioselective attack of the thiol group of the 4-aminothiophenol in the chlorine nucleophilic displacement on 7-chlorothieno[3,2-*b*]pyridine **1**, obtaining the aminated compounds **2a–c**. These were reacted with arylurea reagents to give the corresponding 1,3-diarylureas **3a–c**, **4a–c** and **5a–c** (see scheme).

1-Aryl-3-[3-(thieno[3,2-*b*]pyridin-7-ylthio)phenyl]ureas **4a–c** with the arylurea in the *meta* position relative to the thioether showed the lowest IC₅₀ values (0.4–0.9 μM) in enzymatic assays using VEGFR2 tyrosine kinase domain, and the binding mode for these compounds was predicted by docking simulations.

Acknowledgements: The Foundation for Science and Technology (FCT–Portugal) is acknowledged for financial support through the NMR Portuguese network (Bruker 400 Avance III-Univ Minho). The